Day: November 10, 2022

MONTRÉAL, Nov. 10, 2022 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the fiscal year ended July 31, 2022. “IBEX had an impressive year, with EBITDA reaching a record level”, said Mr. Baehr, IBEX President & CEO. “The strong financial performance resulted from record revenues driven by strong sales of heparinase-based products, and by customers increasing their inventories to protect against supply-chain interruptions.” He further stated: “With customers normalizing their inventories, and with reduced COVID hospitalizations, we expect to see 2023 revenues well below F2022 levels, but greater than seen in F2021. Note: All figures are in Canadian dollars unless otherwise stated. The Company’s audited consolidated financial statements for the year...

REPORTS NET INCOME OF $9.6 MILLION, ADJUSTED EBITDA OF $16.5 MILLION AND FREE CASH FLOW OF $11.2 MILLION HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported third quarter 2022 financial and operating results, as well as material subsequent events following the end of the quarter through the date of this release. Third Quarter Highlights:Maintained total net revenue interest (NRI) production of 27.6 MMcfe/d (Working Interest of 32.0 MMcfe/d) for the three months ended September 30, 2022; Continued to realize strong prices of $7.54/Mcfe including hedges ($7.55/Mcfe excluding hedges) for the three months ended September 30, 2022; Reported total revenues of $21.2 million, an increase of 7% compared to the prior quarter:$19.2 million from natural gas, oil, and NGL...

VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce the Company’s unaudited financial results for the three months ended September 30, 2022 (“Q3 2022”), as well as a summary of recent development highlights at the Company’s Premier Gold Project (“PGP” or the “project”), located on Nisga’a Nation Treaty Lands in the prolific Golden Triangle of northwestern British Columbia. For details of the unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three months ended September 30, 2022, please see the Company’s filings on SEDAR (www.sedar.com). All amounts herein are reported in $000s of Canadian dollars (“C$”) unless otherwise specified. Q3 2022 AND RECENT HIGHLIGHTSThe...

Tom Slater hired as Chief Credit Officer Payment Card Business Triples Since Inception, as Bank Assets Approach $1.1 Billion STAMFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) — Patriot National Bancorp, Inc. (“Patriot,” “Bancorp” or the “Company”) (NASDAQ: PNBK), the parent company of Patriot Bank, N.A. (the “Bank”), today announced net income of $2.3 million, or $0.59 basic and diluted earnings per share for the quarter ended September 30, 2022. These results reflect an increase as compared to $1.3 million, or $0.32 per basic and diluted earnings per share for the second quarter of 2022 and net income of $1.3 million, or $0.34 basic and diluted earnings per share reported in the third quarter of 2021. The 2021 third quarter included the benefit of a non-recurring employee retention tax credit (“ERC”) of $906,000. For the nine months...

Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of DirectorsAgreements with CinRx Pharma and a subsidiary to provide additional capital and access to CinRx’s industry and clinical trial expertise to support advancement of TTP399HIGH POINT, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments. “During the third quarter, we continued working diligently toward the commencement of TTP399...

MONTRÉAL, Nov. 10, 2022 (GLOBE NEWSWIRE) — Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the second quarter of fiscal 2023, which ended on September 30, 2022. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS). “We are pleased with the progress we have made in stabilizing the business while improving our execution. Again, our team’s agility played a pivotal role this quarter as we delivered strong year-over-year growth across key metrics, including revenues, net earnings, adjusted EBITDA1, and adjusted EPS1, driven by our successful efforts to mitigate inflation, our efficiency and productivity, and sustained consumer...

Revenue in USD $ Revenue in USD $Adjusted EBITDA & Operating Income (Loss) in USD $ Adjusted EBITDA & Operating Income (Loss) in USD $NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Nov. 10, 2022 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce the release of financial results for the quarter ended September 30, 2022. All amounts are in United States dollars unless otherwise specified. Nova Leap Q3 2022 Financial Results Financial results for the third quarter ended September 30, 2022 include the following:Q3 2022 revenues were the 2nd highest in the Company’s history; Q3 2022 revenues of $7,141,654 increased by 2.2% relative to Q2 2022 revenues of...

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. “The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101,” said John Orwin, Chief Executive Officer of Atreca. “We remain encouraged by the association we see between clinical activity and target expression, the durability of the clinical activity observed and the tolerability demonstrated in the study. We...

IRVINE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the third quarter 2022, ended September 30, 2022. Third Quarter and Recent Highlights:SWOG Cancer Research Network selected the DetermaIOTM test to be used in its S1418 clinical trial, a prospectively designed biomarker study of breast cancer tissues. DetermaIO sample volume from Early Adopters grew at 117% quarter over quarter. DetermaRxTM test sample volume increased by 51%, compared to third quarter of 2021 and onboarded physician base increased by 62%, as compared to the same period in 2021. Received recommendation from the Advisory...